BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23895135)

  • 1. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
    Jardim DL; Conley A; Subbiah V
    Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
    Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
    Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
    Gatalica Z; Vranic S; Ghazalpour A; Xiu J; Ocal IT; McGill J; Bender RP; Discianno E; Schlum A; Sanati S; Palazzo J; Reddy S; Pockaj B
    Oncotarget; 2016 Jan; 7(2):1707-16. PubMed ID: 26625196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
    Zhou P; Zhang Q; Zhu J; Li P
    Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phyllodes tumors of the breast segregate in two groups according to genetic criteria.
    Laé M; Vincent-Salomon A; Savignoni A; Huon I; Fréneaux P; Sigal-Zafrani B; Aurias A; Sastre-Garau X; Couturier J
    Mod Pathol; 2007 Apr; 20(4):435-44. PubMed ID: 17334353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic characteristics of two breast malignant phyllodes tumors during pregnancy and lactation identified through whole-exome sequencing.
    Lei T; Shen M; Deng X; Shi Y; Peng Y; Wang H; Chen T
    Orphanet J Rare Dis; 2022 Oct; 17(1):382. PubMed ID: 36271373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours.
    Kuijper A; Snijders AM; Berns EM; Kuenen-Boumeester V; van der Wall E; Albertson DG; van Diest PJ
    Cell Oncol; 2009; 31(1):31-9. PubMed ID: 19096148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression.
    Kersting C; Kuijper A; Schmidt H; Packeisen J; Liedtke C; Tidow N; Gustmann C; Hinrichs B; Wülfing P; Tio J; Boecker W; van Diest P; Brandt B; Buerger H
    Lab Invest; 2006 Jan; 86(1):54-61. PubMed ID: 16258523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization.
    Lee J; Wang J; Torbenson M; Lu Y; Liu QZ; Li S
    Cancer Genet Cytogenet; 2010 Jan; 196(2):179-83. PubMed ID: 20082856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
    Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
    Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.
    Egas-Bejar D; Anderson PM; Agarwal R; Corrales-Medina F; Devarajan E; Huh WW; Brown RE; Subbiah V
    Oncoscience; 2014 Mar; 1(2):167-179. PubMed ID: 25126591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome profiling helps to classify phyllodes tumours of the breast.
    Laé M; La Rosa P; Mandel J; Reyal F; Hupé P; Terrier P; Couturier J
    J Clin Pathol; 2016 Dec; 69(12):1081-1087. PubMed ID: 27207013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
    Bot FJ; Sleddens HF; Dinjens WN
    Diagn Mol Pathol; 1998 Dec; 7(6):295-301. PubMed ID: 10207667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups.
    Tan WJ; Lai JC; Thike AA; Lim JC; Tan SY; Koh VC; Lim TH; Bay BH; Tan MH; Tan PH
    Breast Cancer Res Treat; 2014 Jun; 145(3):635-45. PubMed ID: 24831776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.